Castration Resistant Cancer
nMCRPC
nMCRPC is castration-resistant prostate cancer without signs of distant metastases.
Available Treatment Options
PSA Doubling Time (PSADT) greater than 10 months
- Androgen Deprivation Therapy (ADT) + Monitoring
- ADT + other secondary hormone therapy
PSA Doubling Time (PSADT) less than or equal to 10 months
- Androgen Deprivation Therapy (ADT) + Preferred regimens:
- Apalutamide (Erleada)
- Enzalutamide (Xtandi)
- Darolutamide (Nubeqa)
- ADT + other secondary hormone therapy
CLINICAL TRIALS:
NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer Version 4.2023
© National Comprehensive Cancer Network, Inc. 2022. All rights reserved. The complete and current version of the guideline is available at NCCN.org.
IMPORTANT:
This information is provided for educational purposes only to support patients in understanding and discussing appropriate treatment options with their doctors. Included is information from treatment guidelines for doctors and other sources. However, this information should not be considered as patient treatment guidelines or recommendations, but as educational materials only. Patients should discuss treatments identified herein with their doctors to understand the risks and benefits of each based on their personal diagnosis. Treatment decisions should only be made between the patient and his doctor.
